Followers | 2540 |
Posts | 250759 |
Boards Moderated | 35 |
Alias Born | 05/06/2014 |
Monday, March 14, 2016 8:39:47 PM
Source: InvestorsHub NewsWire
Pressure BioSciences to Participate in SCIEX Workshop on New Innovations Towards Industrialized Proteomics at US HUPO Conference
SCIEX Seminar Will Focus on Using Industrialized Omics to Perform Translational Research Needed to Enable Precision Medicine
South Easton, MA -- March 14, 2016 -- InvestorsHub NewsWire -- Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI and the Company), a leader in the development and sale of broadly enabling pressure cycling technology (PCT)-based sample preparation solutions to the worldwide life sciences industry, today announced that SCIEX, a global leader in life science analytical technologies, will present and lead a precision medicine workshop on New Innovations Towards Industrialized Proteomics at the annual conference of the US Human Proteome Organization (US HUPO). US HUPO is being held from March 13-16 in Boston, MA. Representatives from SCIEX, Pressure BioSciences, Inc., and Advaita Bioinformatics will share insightful examples of how SCIEX next-generation solutions are enabling life science researchers to unlock the potential of their discoveries using industrialized omics to enable precision medicine. The workshop will showcase examples of how SCIEXs next-generation mass spectrometry-based solutions, combined with PBIs PCT platform and Advaitas iPathwayGuide, provide the ability to industrialize omics research workflows.
Life science researchers who are striving to transition from basic research to translational research will receive information about providing sample to biology solutions, as well as on accelerating and facilitating the biomarker research pipeline, from discovery and validation to translation into biologically and clinically relevant knowledge. The workshops seminars include:
Mark Cafazzo, Director of Academic Business at SCIEX. Mr. Cafazzo will lead a practical discussion on new technologies for enabling reproducible and biologically meaningful results from proteomics experiments across very large sample cohorts in an effort to Industrialize Proteomics.
Vera Gross, Ph.D., Senior Scientist at PBI. Dr. Gross presentation, entitled From PCT-HD to SWATH Data Acquisition in Half a Day, will include a discussion on advances of quantitative SWATH-MS technology with the introduction of new PCT-based sample preparation techniques and QC kits from PBI.
Andrew Olson, Vice-President of Business Development at Advaita Corporation. Mr. Olsen will present an overview of the iPathway Guide for Next-Gen Proteomics, a cloud-enabled bioinformatics platform.
An audio recording will be made available after the conference. Please contact SCIEXs media contact for access (Patrick Farrell, Sniper Public Relations on behalf of SCIEX, 603-420-8828).
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 260 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.
About SCIEX
SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.
With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit sciex.com. SCIEX social: Twitter: @SCIEXnews, LinkedIn and Facebook.
About Advaita Bioinformatics
Advaita Bioinformatics is a leader in the development of analytic solutions for high-throughput biological data. Founded in 2005 with headquarters near Ann Arbor, Michigan, Advaitas novel analysis helps translate the terabytes of genomic data produced as a result of gene-expression and protein-expression experiments into a better understanding of the underlying biological phenomena. Advaitas patented approach, called Impact Analysis, delivers results and insights that cannot be achieved with any other commercial analysis software. iPathwayGuide is the first web application capable of identifying mechanisms of action, micro-RNAs, genetic variants, and potential drug targets, directly from gene-expression experiments. This unique ability helps researchers quickly zero in on drug targets and validate drug candidates with the greatest potential for success while avoiding costly dead-ends. For more information, please visit http://www.AdvaitaBio.com.
Investor Contacts:
Richard T. Schumacher, President & CEO, PBI (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman, PBI (650) 812-8121 (T)
Redwood Investment Group (714) 978-4425 (T)
For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com
Please visit us on Twitter | LinkedIn | YouTube | Google+ | Facebook
Recent PBIO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/06/2024 09:17:19 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/19/2024 09:20:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 04:32:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/07/2024 09:28:07 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/27/2024 06:42:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 10:30:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:24:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:24:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:24:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:24:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:24:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:24:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:44:21 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 08:18:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2023 02:19:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2023 02:17:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2023 02:14:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2023 02:12:19 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM